Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Keith Manchester Insider Profile
4 Followers
Keith Manchester, Director at Arbutus Biopharma, holds 1.78M shares in Roivant Sciences (Ticker: ROIV), holds 46.07K shares in Arbutus Biopharma (Ticker: ABUS).
Profitable Transactions
0 out of 3 Profitable Transactions
Average Return
-36.50%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Keith Manchester holds in companies
Most Profitable Insider Trade
The most profitable trade made by Keith Manchester
Keith Manchester's Trading History
Arbutus Biopharma
Aug 16, 2024
Director
Uninformative Buy
30.75K
$190.26K
Roivant Sciences
Sep 12, 2024
Director
Uninformative Buy
―
$21.36M
List of latest transactions for each holding click on a transaction to see Keith Manchester's performance on stock
You May Also Like
Keith Manchester insider profile FAQ
What is the percentage of profitable transactions made by Keith Manchester?
The percentage of profitable transactions made by Keith Manchester is 0%.
What is the average return per transaction made by Keith Manchester?
The average return per transaction made by Keith Manchester is -36.50%.
What stocks does Keith Manchester hold?
Keith Manchester holds: ABUS, ROIV stocks.
What was Keith Manchester’s latest transaction?
Keith Manchester latest transaction was an Uninformative Buy of ―.
What was Keith Manchester's most profitable transaction?
Keith Manchester’s most profitable transaction was an Informative Sell of ROIV stock on October 2, 2023. The return on the trade was -13.50%.
What is Keith Manchester's role in Arbutus Biopharma?
Keith Manchester's role in Arbutus Biopharma is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.